Key Points • Dara-KRd–based, MRD-adapted treatment yielded high stringent CR rates and MRD negativity that improved over time.• Results support randomized studies of therapy de-escalation for patients who are MRD(-)… Click to show full abstract
Key Points • Dara-KRd–based, MRD-adapted treatment yielded high stringent CR rates and MRD negativity that improved over time.• Results support randomized studies of therapy de-escalation for patients who are MRD(-) and escalation for MRD(+) after initial treatment.
Keywords:
driven phase;
daratumumab carfilzomib;
phase study;
carfilzomib lenalidomide;
mrd driven;
study daratumumab
Journal Title: Blood Advances
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!